Giant cell arteritis: An updated review of an old disease

Area of Science:

• Rheumatology
• Internal Medicine
• Immunology

Background:

• Giant cell arteritis (GCA) is a prevalent systemic vasculitis primarily affecting older adults.
• GCA presents with diverse clinical manifestations, necessitating physician awareness for timely diagnosis.
• Glucocorticoids are the primary treatment, but their toxicity requires careful management.

Purpose of the Study:

• To highlight the importance of recognizing varied clinical phenotypes of GCA.
• To emphasize prompt initiation of glucocorticoid therapy.
• To introduce tocilizumab as a potential glucocorticoid-sparing agent.

Main Methods:

• Literature review of GCA clinical presentations and treatment strategies.
• Analysis of current therapeutic guidelines for GCA.
• Review of emerging treatments, including biologic agents.

Main Results:

• GCA's variable presentation can delay diagnosis.
• Glucocorticoids are effective but associated with significant adverse effects.
• Tocilizumab (an IL-6 receptor inhibitor) demonstrates potential for reducing glucocorticoid dependence.

Conclusions:

• Early identification of GCA phenotypes is crucial for effective management.
• Managing glucocorticoid toxicity is an essential aspect of GCA care.
• Tocilizumab offers a promising alternative or adjunctive therapy, though further research on its long-term outcomes is needed.